CGEM
Cullinan Therapeutics, Inc.NASDAQHealthcare$14.43+3.52%ClosedMarket Cap: $873.4M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
2.16
P/S
0.00
EV/EBITDA
-3.38
DCF Value
$1.44
FCF Yield
-15.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-46.2%
ROA
-49.0%
ROIC
-58.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-55.3M | $-50.7M | $-0.86 | — |
| FY 2025 | $0.00 | -Infinity% | $-241.6M | $-219.9M | $-3.72 | — |
| Q3 2025 | $0.00 | NaN% | $-55.6M | $-50.6M | $-0.86 | — |
| Q2 2025 | $0.00 | NaN% | $-75.8M | $-70.1M | $-1.19 | — |
| Q1 2025 | $0.00 | NaN% | $-55.0M | $-48.5M | $-0.82 | — |
| Q4 2024 | $0.00 | NaN% | $-55.0M | $-47.6M | $-0.81 | — |
| FY 2024 | $0.00 | -Infinity% | $-196.9M | $-167.4M | $-3.11 | — |
| Q3 2024 | $0.00 | NaN% | $-48.9M | $-40.6M | $-0.70 | — |
| Q2 2024 | $0.00 | -Infinity% | $-50.0M | $-42.0M | $-0.76 | — |
| Q1 2024 | $0.00 | -Infinity% | $-43.0M | $-37.1M | $-0.86 | — |
| Q4 2023 | $0.00 | -Infinity% | $-45.5M | $-23.8M | $-0.56 | — |
| FY 2023 | $0.00 | NaN% | $-191.1M | $-153.2M | $-3.69 | — |